UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) September 7, 2006
|
Advaxis,
Inc.
|
|
(Exact
name of registrant as specified in its
charter)
|
|
Delaware
|
00028489
|
84-1521955
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
Technology
Center of New Jersey,
675
Rt. 1, St. 113
North
Brunswick, New Jersey
|
08902
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (732)
545-1590
|
(Former
name or former address, if changed since last
report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
| Item 5.02. |
Departure
of Directors or Principal Officers; Election of Directors; Appointment
of
Principal Officers
|
Effective
September 7, 2006, Mr. J. Todd Derbin resigned as a member of the Registrant’s
Board of Directors. Such resignation was not the result of any disagreement
between the Registrant and Mr. Derbin. See Mr. Derbin’s resignation letter
attached as Exhibit 17.
Effective
September 7, 2006, the Board of Directors of the Registrant nominated and
elected Mr. Thomas A. Moore to fill the vacancy created by Mr. Derbin’s
resignation. Mr. Moore currently also serves as a Board member for Alteon,
Inc.,
a publicly traded developer of pharmaceuticals for the treatment of diabetes
and
age-related diseases, El Dorado Inc., a targeted marketer to unassimilated
Hispanics, Medmeme’,
which
measures medical education effectiveness, and Opt-e-scrip, Inc. , which markets
a clinical system to compare multiple drugs in the same patient. He also serves
as Chairman at Mayan Pigments, Inc., which has developed and patented Mayan
pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was
President and Chief Executive Officer of Biopure Corporation, a developer of
oxygen therapeutics that are intravenously administered to deliver oxygen to
the
body’s tissues. From 1996 to November 2000 he was President and Chief Executive
Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career
with the Procter & Gamble Company in multiple managerial positions,
including president of Health Care Products where he was responsible for
prescription and over-the-counter medications worldwide, and group vice
president of the Procter & Gamble Company.
Mr.
Moore
is a defendant in a civil enforcement action captioned Securities
& Exchange Commission v. Biopure Corp. et al.,
No.
05-11853-PBS (D. Mass.), filed on September 14, 2005, which alleges that Mr.
Moore made and approved misleading public statements about the status of FDA
regulatory proceedings concerning a product manufactured by his former employer,
Biopure Corp. Mr. Moore has denied all allegations and is vigorously defending
the action.
| Item 9.01. |
Financial
Statements and
Exhibits
|
a)
Not applicable.
b)
Not
applicable.
c) Exhibits
| 17. |
Letter
from resigning director J. Todd Derbin, dated September 7,
2006.
|
2
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: September
14, 2006
|
ADVAXIS,
INC.
|
||
| |
|
|
| By: | /s/ Roni Appel | |
|
Name: Roni
Appel
Title:
President and Chief
Executive
Officer
|
||
3
